AbbVie Partners With Valkai on AI Tools for Clinical Development
Sep 29, 2026
Biotech
AbbVie Acquires Gilgamesh Pharmaceuticals' Psychedelic Candidate Bretisilocin
Oct 20, 2025
AbbVie has completed the acquisition of Gilgamesh Pharmaceuticals’ investigational compound bretisilocin, a next-generation psychedelic currently in Phase 2 trials for major depressive disorder.
AbbVie has completed the acquisition of Gilgamesh Pharmaceuticals' investigational compound bretisilocin, announced in a press release. The compound is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for moderate-to-severe major depressive disorder.
Bretisilocin is designed as a next-generation psychedelic compound intended to address challenges seen with traditional psychedelics. AbbVie stated that recent clinical data suggest the compound has potential as a treatment for patients with major depressive disorder.
With the acquisition finalized, AbbVie plans to accelerate bretisilocin’s development as part of its psychiatry pipeline expansion.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Oct 16 RapidCanvas Raises $29 Million to Expand Enterprise AI Platform Oct 16 KBRA Rated Anthropic BB+ Before $35 Billion Chip Financing Oct 16 Goodweek Raises $12 Million for AI Management Platform Oct 16 Intuit Agrees to Acquire AI Billing Startup Sequence for Reported $200 Million Oct 16 Matters Raises $5 Million to Build AI Consumer BankMore from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsFree newsletter
AI Funding Brief
Market report
.png)
2025 Generative AI in Professional Services Report
Thomson Reuters
This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.
Read moreYou may also like
Insilico Medicine Selects AI Designed Obesity Drug Candidate ISM1354
Sep 30, 2026
Biotech
Zealand Pharma signs AI obesity drug deal worth up to $1.2 billion
Oct 15, 2026
Biotech
Basecamp Research Raises $140 Million for AI Designed Therapeutics
Sep 24, 2026
Funding
Sopris Capital Acquires Blackford Analysis from Bayer
Oct 12, 2026
Acquisitions
Inductive Bio launches Beacon-2 to predict human drug doses
Sep 17, 2026
Biotech
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.